Last reviewed · How we verify

NCT01497067

Long Term Safety Protocol for the AcrySof CACHET Phakic Lens

Completed NA Results posted Last updated 2 July 2019
What this trial tests

NA trial testing ACRYSOF CACHET Phakic Lens (L-series) in Myopia in 657 participants. Completed in 15 June 2018.

Timeline
21 November 2011
Primary endpoint
15 June 2018
15 June 2018

Quick facts

Lead sponsorAlcon Research
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment657
Start date21 November 2011
Primary completion15 June 2018
Estimated completion15 June 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Alcon Research — full company profile →

Who can join

18 and older, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Central Endothelial Cell Density (All Eyes) Primary · Year 4 to Year 10 postoperative from previous study (C-02-23, C-02-40, C-03-21, and C-05-57)

A microscope was used to photograph corneal endothelial cells (cells on the back of the cornea). Three images at the center of the cornea were obtained and sent to a central reading center for analysis. All recorded data from images were used in the analysis. A higher value for density represents a healthier cornea.

Year 4
GroupValue95% CI
CACHET2654.0± 354.6
Year 5
GroupValue95% CI
CACHET2639.0± 324.2
Year 5.5
GroupValue95% CI
CACHET2633.0± 357.6
Year 6
GroupValue95% CI
CACHET2551.0± 362.3
Year 6.5
GroupValue95% CI
CACHET2524.7± 360.6
Year 7
GroupValue95% CI
CACHET2504.9± 365.8
Year 7.5
GroupValue95% CI
CACHET2497.1± 364.7
Year 8
GroupValue95% CI
CACHET2465.0± 384.2

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events were collected from time of enrollment until study exit for an individual duration up to 6 years based on time of enrollment.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

CACHET - Ocular
Serious: 276/1123 (25%)
Deaths: 0/1123
CACHET - Systemic
Serious: 24/657 (4%)
Deaths: 3/657

Serious adverse events (75 terms)

ReactionSystemCACHET - OcularCACHET - Systemic
Intraocular lens extractionSurgical and medical procedures
Corneal endothelial cell lossEye disorders
Iris adhesionsEye disorders
Cataract nuclearEye disorders
Intraocular lens implantSurgical and medical procedures
CataractEye disorders
Visual acuity reducedEye disorders
Intraocular pressure increasedInvestigations
Cataract subcapsularEye disorders
KeratomileusisSurgical and medical procedures
Cataract corticalEye disorders
Device dislocationGeneral disorders
Retinal laser coagulationSurgical and medical procedures
GlaucomaEye disorders
Pupillary deformityEye disorders
Lenticular opacitiesEye disorders
Open angle glaucomaEye disorders
Corneal operationSurgical and medical procedures
Ocular hypertensionEye disorders
RetinopexySurgical and medical procedures
Angle closure glaucomaEye disorders
Retinal detachmentEye disorders
Visual acuity tests abnormalInvestigations
IridotomySurgical and medical procedures
VitrectomySurgical and medical procedures

Most-reported serious reactions: Intraocular lens extraction, Corneal endothelial cell loss, Iris adhesions, Cataract nuclear, Intraocular lens implant, Cataract, Visual acuity reduced, Intraocular pressure increased.

Data from ClinicalTrials.gov NCT01497067 adverse events section.

Sponsor's own description

The purpose of this long term safety study is to estimate the annualized endothelial cell loss (ECL) rate (for up to 10 years following date of implantation) of subjects previously implanted with the ACRYSOF CACHET Phakic Intraocular Lens (L-series) from precursor clinical studies C-02-23, C-02-40, C-03-21 and C-05-57.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Alcon Research trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01497067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing